Granted Patent
B2
US 12,371,473 · App. 17/813,857 · Granted Jul 29, 2025
Therapeutic biologic for treatment of hepatocellular carcinoma
Assignee:
Circular Commitment Company
C07K14/745A61K47/65A61K47/6811A61K47/6849A61K47/6851C07K16/30A61K2039/505C07K16/28C07K2317/24C07K2317/34C07K2317/55C07K2317/565C07K2317/92C07K2319/035C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
Claims (23)
1. A nucleic acid encoding a conjugate comprising a tissue factor (TF) comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1 conjugated via a linker peptide to an antibody that binds an extracellular domain epitope of human plasmalemma vesicle associated protein (PLVAP), wherein the antibody comprises:
a complementarity determining regions (CDRs) 1-3 of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 3, and CDRs 1-3 of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 4; or
b) CDRs 1-3 of a HCVR comprising the amino acid sequence of SEQ ID NO: 5, and CDRs 1-3 of a LCVR comprising the amino acid sequence of SEQ ID NO: 6.
2. The nucleic acid of claim 1 , wherein the antibody comprises a LCVR comprising the amino acid sequence of SEQ ID NO: 4 and a HCVR comprising the amino acid sequence of SEQ ID NO: 3, or a LCVR comprising the amino acid sequence of SEQ ID NO: 6 and a HCVR comprising the amino acid sequence of SEQ ID NO: 5.
3. The nucleic acid of claim 2 , wherein the LCVR, or HCVR, or both, are humanized.
4. The nucleic acid of claim 3 , wherein the LCVR and HCVR comprise:
a) a HCVR sequence selected from SEQ ID NO: 7, 8, 9, 10, and 11; and a LCVR sequence selected from SEQ ID NO: 12, 13, and 14; or
b) a HCVR sequence selected from SEQ ID NO: 15, 16, 17, 18, and 19; and a LCVR sequence selected from SEQ ID NO: 20, 21, and 22.
5. The nucleic acid of claim 1 , wherein the tissue factor (TF) comprises the amino acid sequence of SEQ ID NO: 1.
6. The nucleic acid of claim 1 , wherein the conjugate comprises an amino acid sequence identical to SEQ ID NO: 23.
7. The nucleic acid of claim 4 , wherein the HCVR sequence comprises SEQ ID NO: 11 and the LCVR sequence comprises SEQ ID NO: 13; or the HCVR sequence comprises SEQ ID NO: 19 and the LCVR sequence comprises SEQ ID NO: 22.
8. A vector comprising the nucleic acid of claim 1 .
9. A host cell comprising the nucleic acid of claim 1 .
10. The host cell of claim 9 , wherein the nucleic acid is included in a vector.
11. The host cell of claim 9 , wherein the host cell is a bacterial cell.
12. The host cell of claim 11 , wherein the bacterial cell is Escherichia coli.
13. The host cell of claim 9 , wherein the host cell is a eukaryotic cell selected from a fungus, an insect cell, and a mammalian cell.
14. The host cell of claim 13 , wherein the fungus is yeast.
15. The host cell of claim 13 , wherein the insect cell is any one or more of Sf0 cell or Sf21 cell.
16. The host cell of claim 13 , wherein the mammalian cell is any one or more of CHO cell, VERO cell, or COS cell.
17. A method of making a conjugate comprising a coagulating agent conjugated to an antibody that binds an extracellular domain epitope of human PLVAP, comprising culturing the host cell of claim 9 under conditions that support the expression of the conjugate by the host cell, and isolating the expressed conjugate.
18. The nucleic acid of claim 1 , wherein the linker peptide comprises a sequence (Gly 4 -Ser (SEQ ID NO: 49)) n , wherein n is 3, 4, 5, or 6.
19. The nucleic acid of claim 18 , wherein the linker peptide comprises the sequence (Gly 4 -Ser (SEQ ID NO: 49)) n , wherein n is 3.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 20, 2022
From: KAO, KUO-JANG; WANG, YUN-HSIN
To: CHINA SYNTHETIC RUBBER CORPORATION
Reel/Frame 061153/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 20, 2022
From: CHINA SYNTHETIC RUBBER CORPORATION
To: INTERNATIONAL CSRC INVESTMENT HOLDINGS CO., LTD.
Reel/Frame 061153/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 20, 2022
From: INTERNATIONAL CSRC INVESTMENT HOLDINGS CO., LTD.
To: CIRCULAR COMMITMENT COMPANY
Reel/Frame 061153/0664 →
Continuity (5)
Provisional Application
61904951
· Nov 15, 2013
References Cited (182)
US 6875570B2
· Gerlach et al.
· 2005
[cited by applicant]
US 8815240B2
· Kao
· 2014
[cited by examiner]
US 8821880B2
· Kao
· 2014
[cited by examiner]
US 9394359B2
· Kao
· 2016
[cited by examiner]
US 9493522B2
· Wells et al.
· 2016
[cited by applicant]
US 9493552B2
· Kao et al.
· 2016
[cited by applicant]
US 9545443B2
· Kao
· 2017
[cited by examiner]
US 20080233117A1
· Roberts et al.
· 2008
[cited by applicant]
US 20090169638A1
· Davis et al.
· 2009
[cited by applicant]
US 20110159498A1
· Kao et al.
· 2011
[cited by applicant]
US 20120178908A1
· Hilden et al.
· 2012
[cited by applicant]
CN 1251532A
· 2000
[cited by applicant]
JP 2013503140A
· 2013
[cited by applicant]
TW 200714294A
· 2007
[cited by applicant]
WO WO1996001653
· 1996
[cited by applicant]
WO WO1998031394A2
· 1998
[cited by applicant]
WO WO2003010336A2
· 2003
[cited by applicant]
WO WO2003023008A2
· 2003
[cited by applicant]
WO WO2003024392A2
· 2003
[cited by applicant]
WO WO2006105361A2
· 2006
[cited by applicant]
WO WO2006110593A2
· 2006
[cited by applicant]
WO WO2008091781A1
· 2008
[cited by applicant]
WO WO2009117096A1
· 2009
[cited by applicant]
WO WO2009126271A1
· 2009
[cited by applicant]
WO WO2010051105A1
· 2010
[cited by applicant]
WO WO2011023785A1
· 2011
[cited by applicant]
Almagro & Franssen, Frontiers in Bioscience, 13:1619-33 (2008).
[cited by examiner]
Edwards et al., J Mol Biol 334:103-118 (2003).
[cited by examiner]
Marchalonis et al., Dev & Comp Immunol. 30:223-247 (2006).
[cited by examiner]
Lippow et al., Nature Biotechnology, 25(10):1171-1176 (2007).
[cited by examiner]
Sulea et al., Scientific Reports, 8(260):1-11 (2018).
[cited by examiner]
Hasegawa et al., MABS, vol. 9, No. 5, pp. 854-873 (2017).
[cited by examiner]
Altshuler et al., Biochemistry (Moscow), 75(13):1584-1605 (2010).
[cited by examiner]
Vajda et al., Current Opinion in Structural Biology, 67 pp. 226-231 (2021).
[cited by examiner]
Marks et al., J. Biol. Chem. 295(29) 9823-9837 (2020).
[cited by examiner]
Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021.
[cited by examiner]
Lo et al., BMC Genomics vol. 22, Article No. 116 (2021).
[cited by examiner]
ThermoFisher product data sheet (High Five™ Cells in Express Five™ Medium; pp. 1-6 (Dec. 31, 2024)).
[cited by examiner]
U.S. Appl. No. 19/014,483, Kao; Kuo-Jang.
[cited by examiner]
“
[cited by applicant]
“Survival Rates for Liver Cancer”, 2 pages. URL: http://www/cancer.org/camcer/livercancer/detailedguide/liver-cancer-survival-rates, downloaded from American Cancer Society website on Aug. 25, 2015.
[cited by applicant]
URL: http://www/cancer.org/camcer/livercancer/detailedguide/liver-cancer-survival-rates, downloaded from American Cancer Society website on Aug. 25, 2015.
[cited by applicant]
Bergers, G., and Coussens, L. M., “Extrinsic regulators of epithelial tumor progression: metalloproteinases,” Current Opinion in Genetics & Development, 10: 120-127 (2000).
[cited by applicant]
Bernard, A., et al., “A Unique Epitope on the CD2 Molecule Defined by the Monoclonal Antibody 9-1: Epitope-Specific Modulation of the E-Rosette Receptor and Effects on T-Cell Functions,” Human Immunology, 17: 388-405 (1…
[cited by applicant]
Brorson K., et al., “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies”, J. Immunol. 163; 6694-6701 (1999).
[cited by applicant]
Bruix, J. and Sherman, M., “Management of Hepatocellular Carcinoma: An Update”, Hepatology, 53(3): 1020-1022 (2011).
[cited by applicant]
Brummell et al., “Probing the combining site of an anti-carbohydrate antibody by saturation-mutagensis: role of the heavy chain DCR3 residues”, Biochemistry 32; 1180-1187 (1993).
[cited by applicant]
Burks et al., “In vitro scanning saturation mutagenesis of an antibody binding pocket”, PNAS 94; 412-417 (1997).
[cited by applicant]
Caldas, C., et al., “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen,” Molecular Immunology, 39: 941-952 (2003).
[cited by applicant]
Carson-Walter, E. B., et al., “Plasmalemmal Vesicle Associated Protein-1 Is a Novel Marker Implicated in Brain Tumor Angiogenesis,” Clin. Cancer Res., 11(21): 7643-7650 (2005).
[cited by applicant]
Casset, F., et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochemical and Biophysical Research Communications, 307: 198-205 (2003).
[cited by applicant]
Chen, X. et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv. Drug Deliv. Rev, vol. 65; No. 10; 1357-1369 (2013).
[cited by applicant]
Chien, N. C., et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism,” Proc. Natl. Acad. Sci. USA, 86: 5532-5536 (1989).
[cited by applicant]
Colman, “A Structural View of Immune Recognition by antibodies”, Research in Immunol. 145; 33-36 (1994).
[cited by applicant]
De Pascalis, R., et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibo…
[cited by applicant]
Dennis, C., “Off by a whisker,” Nature, 442: 739-741 (2006).
[cited by applicant]
Developmental Studies Hybridoma Bank (search for MECA-32 antibody; pp. 1-12; Jul. 31, 2018).
[cited by applicant]
Din HM et al., Relationship between tissue factor expression and angiogenesis of hepatocellular carcinoma and its clinical significance. J. Hepatopancreatobiliary Surgery, Sep. 2008, vol. 20, No. 5, pp. 331-335.
[cited by applicant]
Frankel A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein engineering, 2000, V. 13, N. 8, p. 575-581, abstract, p. 579-580.
[cited by applicant]
Giusti, A. M., et al., “Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region,” Proc. Natl. Acad. Sci. USA, 84: 2926-293…
[cited by applicant]
Gotoh, K., et al., “Apg-2 has a chaperone-like activity similar to Hsp110 and is overexpressed in hepatocellular carcinomas,” FEBS Letters, 560: 19-24 (2004).
[cited by applicant]
Gray, D., et al., “Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers,” Cancer Res., 65(21): 9751-9761 (2005).
[cited by applicant]
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,” Science, 278: 1041-1042 (1997).
[cited by applicant]
Güssow, D., and Seemann, G., “Humanization of Monoclonal Antibodies,” Methods in Enzymology, 203: 99-121 (1991).
[cited by applicant]
Hayward, D. G., et al., “The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer,” Cancer Research, 64: 7370-7376 (2004).
[cited by applicant]
Hegmans, J. P. J. J., et al., “Proteomic Analysis of Exosomes Secreted by Human Mesothelioma Cells,” Am. J. Pathol., 164(5): 1807-1815 (2004).
[cited by applicant]
Henry, M. D., et al., “A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Cojugate Designed for the Treatment of Prostate Cancer,” Cancer Research, 64: 7995-8001 (2004).
[cited by applicant]
Herrnberger, L et al., “The role of plasmalemma vesicle-associated protein (PLVAP) in andothelial cells of Schlemm's canal and ocular capillaries,” Experimental Eye Research, vol. 105; 27-33 (2012).
[cited by applicant]
Ho, S., et al., “Internal Radiation Therapy for Patients with Primary or Metastatic Hepatic Cancer,” Cancer, 83: 1894-1907 (1998).
[cited by applicant]
Holm, P., et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Molecular Immunology, 44: 1075-1084 (2007).
[cited by applicant]
Hu P. et al., Comparison of the three different targeted tissue factor fusion proteins for inducing a tumor vessel thrombosis, Cancer Research, 2003, V. 63, N. 16, p. 5046-5053, Full Text, pp. 5046-5048.
[cited by applicant]
Huang, M. et al., “The Mechanism of an Inhibitory Antibody on TF-initiated Blood Coagulation Revealed by the Crystal Structures of Human Tissue Factor, Fab 5G9 and TF 5G9 Complex,” J. Mol. Biol., vol. 275; 873-894 (1998…
[cited by applicant]
Huang ZJ et al., Humanised monoclonal antibody TNT-3 mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice. Chin J Oncol., Apr. 2012, vol. 34, No. 4, pp. 249-253.
[cited by applicant]
Huang, X., et al., “Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature”, Science, 275: 547-550 (1997).
[cited by applicant]
Jang et al., “The structural basis for DNA binding by an anti-DNA autoantibody”, Molec. Immunol. 35; 1207-1217 (1998).
[cited by applicant]
Jemal, A., et al., “Global Cancer Statistics”, CA Cancer J Clin, 51: 69-90 (2011).
[cited by applicant]
Jiang, B., ct al., “A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2,” J. Biol. Chem., 280(6): 4656-4662 (2005).
[cited by applicant]
Kelland, L. R., “'Of mice and men': values and liabilities of the athymic nude mouse model in anticancer drug development,” Eur. J. Cancer, 40: 827-836 (2004).
[cited by applicant]
Keuschnigg, J., et al., “The Prototype Endothelial Marker PAL-E is a Leukocyte Trafficking Molecule”, Blood, 114(2): 478-484 (2009).
[cited by applicant]
Klein, F. et al., Somatic mutations of the Immunoglobulin Framework are Generally Required for Broad and Potent HIV-1 Neutralization, Cell, vol. 153; No. 1; 126-138 (2013).
[cited by applicant]
Kobayashi et al., “Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody”, Protein Engineering 12; 879-844 (1999).
[cited by applicant]
Lee, J.-S., et al., “Classification and Prediction of Survival in Hepatocellular Carcinoma by Gene Expression Profiling,” Hepatology, 40: 667-676 (2004).
[cited by applicant]
Lin, M.-L., et al., “Involvement of maternal embryonic leucine zipper kinase (MELK) in mammmary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family,” Breast Cancer Research, 9: R17 …
[cited by applicant]
Liu, Z., et al., “Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from Drosophila melanogaster,” J. Mol. Recognit., 12: 103-111 (1999).
[cited by applicant]
Llovet, J.M., et al., “Systematic Review of Randomized Trials for Unresectable Hepatocellular Carcinoma: Chemoembolization Improves Survival”, Hepatology, 37: 429-442 (2003).
[cited by applicant]
Llovet, J.M., et al., “Sorafenib in Advanced Hepatocellular Carcinoma”, The New England Journal of Medicine, 359: 378-390 (2008).
[cited by applicant]
MacCallum, R. M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 262: 732-745 (1996).
[cited by applicant]
Mackman, Nigel, “Role of Tissue Factor in Hemostasis, Thrombosis, and Vascular Development”, Arterioscler Thromb Vasc Biol, 24: 1015-1022 (2004).
[cited by applicant]
Madden, S.L., et al., “Vascular Gene Expression in Nonneoplastic and Malignant Brain”, American Journal of Pathology, 165(2): 601-608 (2004).
[cited by applicant]
Mariuzza, R. A., et al., “The Structural Basis of Antigen-Antibody Recognition,” Ann. Rev. Biophys. Biophys. Chem., 16: 139-159 (1987).
[cited by applicant]
Mcdevitt, M. R., et al., “An α-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer,” Cancer Research, 60: 6095-6100 (2000).
[cited by applicant]
Murata, S., et al., “Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma”, The Scientific World Journal, Article ID 479805; 8 pages (2013).
[cited by applicant]
Nishi, Y., et al., “Histopathological manifestations of membranoproliferative glomerulonephritis and glomerular expression of plasmalemmal vesicle-associated protein-1 in a patient with polycythemia vera,” Clinical Neph…
[cited by applicant]
Nuyten, D. S. A., et al., “Using Microarray Analysis as a Prognostic and Predictive Tool in Oncology: Focus on Breast Cancer and Normal Tissue Toxicity,” Seminars in Radiation Oncology, 18: 105-114 (2008).
[cited by applicant]
Ørntoft, T. F., et al., “Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-invasive and Invasive Human Transitional Cell Carconomas,” Molecular & Cellular Proteomics, 1: 37-45 (2002…
[cited by applicant]
Pakula A.A. et al., Genetic analysis of protein stability and function, Annual review of genetics, 1989, V. 23, N. 1, p. 289-310, p. 305-306.
[cited by applicant]
Perz, J.F., et al., “The Contributions of Hepatitis B Virus and Hepatitis C virus Infections to Cirrhosis and Primary Liver Cancer Worldwide”, Journal of Hepatology, 45: 529-538 (2006).
[cited by applicant]
Petersen, L.C., et al., “Characterization of Recombinant Murine Factor IIa and Recombinant Murine Tissue Factor: A Human-Murine Compatibility Study”, Thrombosis Res, 116: 75-85 (2005).
[cited by applicant]
Pettersen, R. D., et al., “CD47 Signals T Cell Death,” J. Immunol., 162: 7031-7040 (1999).
[cited by applicant]
Philipp, J., et al., “Soluble Tissue Factor Induces Coagulation on Tumor Endothelial Cells In Vivo if Coadministered With Low-Dose Lipopolysaccharides”, Arterioscler Thromb Vasc Biol, 23: 905-910 (2003).
[cited by applicant]
Ran, S. et al., “Infraction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature,” Cancer Research, vol. 58; 4646-4653 (1998).
[cited by applicant]
Rantakari P. et al., The endothelial protein PLVAP in lymphatics controls the entry of lymphocytes and antigens into lymph nodes, Nature immunology, 2015, V. 16, N. 4, p. 386-401, Full Text, p. 387-389.
[cited by applicant]
Rhodes, D. R., et al., “Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression,” PNAS, 101(25): 9309-9314 (2004).
[cited by applicant]
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79: 1979-1983 (1982).
[cited by applicant]
Safdari, Y. et al., “Antibody humanization methods—a review and update,” Biotechnology and Genetic Engineering Reviews, vol. 29; No. 2; 175-186 (2013).
[cited by applicant]
Saijo, N., “What are the reasons for negative phase III trials of molecular-target-based drugs?” Cancer Sci., 95: 772-776 (2004).
[cited by applicant]
Schier, R., ct al., “Isolation of Picomolar Affinity Anti-c-crbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site,” J. Mol. Biol., 263: 551-5…
[cited by applicant]
Shchegolev A.A et al., Vascularization of the tissuc of hepatocellular carcinoma depends on the degree of its differentiation, Bulletin of Experimental Biology and Medicine, 2012, p. 153, N. 4, p. 480-484, Full Text.
[cited by applicant]
Siegel, R., et al., “Cancer Statistics, 2012”, CA Cancer J Clin, 62: 10-29 (2012).
[cited by applicant]
Simard, E.P., et al., “Cancers With Increasing Incidence Trends in the United States: 1999 Through 2008”, CA Cancer J Clin, 62: 118-128 (2012).
[cited by applicant]
Simonetti, R.G., et al., “Hepatocellular Carcinoma. A Worldwide Problem and the Major Risk Factors”, Dig Dis Sci, 36: 962-972 (1991).
[cited by applicant]
Skerra A. et al., Assembly of a functional immunoglobulin Fv fragment in
[cited by applicant]
Snyder, L.A., et al., “Expression of Human Tissue Factor Under the Control of the Mouse Tissue Factor Promoter Mediates Normal Hemostasis in Knock-In Mice”, Journal of Thrombosis and Haemostasis, 6: 306-314 (2007).
[cited by applicant]
Sotiriou, C. et al., “Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade to Improve Prognosis,” Journal of the National Cancer Institute, vol. 98; No. 4; 262-272 (2006).
[cited by applicant]
Stan, R.-V., et al., “Immunoisolation and Partial Characterization of Endothelial Plasmalemmal Vesicles (Caveolae),” Molecular Biology of the Cell, 8: 595-605 (1997).
[cited by applicant]
Stan, R. V., et al., “PV1 Is a Key Structural Component for the Formation of the Stomatal and Fenestral Diaphragms,” Molecular Biology of the Cell, 15: 3615-3630 (2004).
[cited by applicant]
Stan, R.-V., et al., “PV-1 is a Component of the Fenestral and Stomatal Diaphragms in Fenestrated Endothelia”, PNAS, 96(23): 13202-13207 (1999).
[cited by applicant]
Stancovski, I., et al., “Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth,” Proc. Natl. Acad. Sci. USA, 88: 8691-8695 (1991).
[cited by applicant]
Strickland, L. A., et al., “Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF),” J. Pathol., 206: 466-475 (2005).
[cited by applicant]
Thorgeirsson, S. S., et al., “Molecular prognostication of liver cancer: End of the beginning,” Journal of Hepatology, 44: 798-805 (2006).
[cited by applicant]
Vajdos, F. F., et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol., 320: 415-428 (2002).
[cited by applicant]
Van 't Veer, L. J., et al., “Gene expression profiling predicts clinical outcome of breast cancer,” Nature, 415: 530-536 (2002).
[cited by applicant]
Wang et al., “Plasmalemmal Vesicle Associated Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma”, BMC Cancer 14: 815-826 (2014).
[cited by applicant]
Winkler, K., et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody,” J. Immunol., 165: 4505-4514 (2000).
[cited by applicant]
Wolff, A. C., et al., “American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer,” Arch. Pathol. Lab. Med., 13…
[cited by applicant]
Wu, H., et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J. Mol. Biol., 294(1): 151-162 (1999).
[cited by applicant]
Corrected Notice of Allowability from U.S. Appl. No. 13/126,734, mailed Apr. 8, 2014.
[cited by applicant]
European Search Report for European Patent Application No. EP14275235, “Therapeutic Biologic for Treatment of Hepatocellular Carcinoma”, dated Aug. 6, 2015. (4261.1003-007).
[cited by applicant]
Final Office Action from U.S. Appl. No. 12/933,248, mailed Nov. 22, 2013.
[cited by applicant]
Final Office Action from U.S. Appl. No. 14/539,577, mailed Apr. 18, 2016.
[cited by applicant]
Final Office Action from U.S. Appl. No. 15/270,430, mailed Aug. 6, 2018.
[cited by applicant]
International Preliminary Report on Patentability from International Application No. PCT/US2009/001689, “Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma,” mailed Sep. 30, 2010.
[cited by applicant]
International Preliminary Report on Patentability from International Application No. PCT/US2009/002196, “Methods, Agents and Kits for the Detection of Cancer,” dated Oct. 12, 2010.
[cited by applicant]
International Preliminary Report on Patentability from International Application No. PCT/US2009/056382, “Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma,” mailed May 12, 2011.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2009/001689, “Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcin…
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2009/002196, “Methods, Agents and Kits for the Detection of Cancer,” mailed Jul. 24, 2009.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority from International Application No. PCT/US2009/056382, “Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcin…
[cited by applicant]
Interview Summary for U.S. Appl. No. 12/933,248, mailed May 29, 2014.
[cited by applicant]
Interview Summary for U.S. Appl. No. 13/126,734, mailed Feb. 6, 2014.
[cited by applicant]
Notice of Abandonment for U.S. Appl. No. 12/937,207, mailed Sep. 26, 2013.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/335,129, mailed Sep. 13, 2016.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/336,441, mailed Apr. 12, 2016.
[cited by applicant]
Notice of Allowance from U.S. Appl. No. 12/933,248, mailed Feb. 14, 2014.
[cited by applicant]
Notice of Allowance from U.S. Appl. No. 13/126,734, mailed Mar. 12, 2014.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/539,577, mailed Jun. 30, 2016.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/370,711, mailed Mar. 27, 2019.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/270,430, mailed Apr. 24, 2019.
[cited by applicant]
Office Action for U.S. Appl. No. 14/335,129, mailed Feb. 19, 2016.
[cited by applicant]
Office Action for U.S. Appl. No. 14/336,441, mailed Dec. 30, 2015.
[cited by applicant]
Office Action from U.S. Appl. No. 12/933,248, mailed May 21, 2013.
[cited by applicant]
Office Action from U.S. Appl. No. 15/270,430, mailed Mar. 2, 2018.
[cited by applicant]
Office Action from U.S. Appl. No. 15/270,430, mailed Nov. 13, 2018.
[cited by applicant]
Office Action from U.S. Appl. No. 13/126,734, mailed Aug. 28, 2013.
[cited by applicant]
Office Action from U.S. Appl. No. 14/539,577, entitled: “Therapeutic Biologic for Treatment of Hepatocellular Carcinoma”, mailed Jan. 8, 2016.
[cited by applicant]
Office Action for U.S. Appl. No. 15/370,711, mailed Oct. 19, 2018.
[cited by applicant]
Response to Rule 312 Communication for U.S. Appl. No. 13/126,734, entitled: “Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma”, mailed Aug. 4, 2014.
[cited by applicant]
Response to Rule 312 Communication for U.S. Appl. No. 14/336,441, entitled: “Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma”, mailed May 20, 2016.
[cited by applicant]
Singapore International Search Report for Application No. 10201407557V, entitled: “Therapeutic Biologic for Treatment of Hepatocellular Carcinoma ,” mailed Aug. 8, 2017.
[cited by applicant]
Office Action for U.S. Appl. No. 16/116,644, mailed May 18, 2020.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/116,644, mailed Sep. 8, 2020.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/116,644, mailed Sep. 23, 2020.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/450,370, mailed Feb. 11, 2022.
[cited by applicant]
Office Action for U.S. Appl. No. 16/513,148, mailed Mar. 23, 2022.
[cited by applicant]
Burrows, F.J., et al., “A Murine Model for Antibody-Directed Targeting of Vascular Endothelial Cells in Solid Tumors”, Cancer Research, 52: 5954-5962 (1992).
[cited by applicant]
Gonzales et al., “Minimizing the immunogenicity of antibodies for clinical application”, Tumour. Biol., vol. 26, No. 1, Jan.-Feb. 2005, pp. 31-43.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/513,148, mailed Aug. 23, 2022.
[cited by applicant]
Yang Jiahui et al. “Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.” PloS one vol. 6; No. 6; e21018; 15 pages (2011).
[cited by applicant]